Conference Coverage: ASCO 2024 – Focus on Lung Cancer

Expert perspectives and strategic insights on the latest therapeutic developments and translational research in lung cancer treatment

June 10, 2024
Corey Langer MD Scientific Leader Faculty Chair Aptitude Health

Faculty Chair

Corey J. Langer, MD, FACP

University of Pennsylvania, Philadelphia, PA, USA


Marina Garassino, MD
University of Chicago, IL, USA

Nasser Hanna, MD
Indiana University School of Medicine, Indianapolis, IN, USA

Ignacio Wistuba, MD
MD Anderson Cancer Center, Houston, TX, USA

Mark Socinski, MD
AdventHealth Cancer Institute, Orlando, FL, USA

Roy Herbst, MD, PhD
Yale Cancer Center, New Haven, CT,  USA

Benjamin Besse, MD, PhD
Institute Gustave Roussy, Villejuif, France

Solange Peters, MD, PhD
University of Lausanne, Switzerland

Enriqueta Felip, MD, PhD
Vall d’Hebron University Hospital, Barcelona, Spain

Sample Report

Start discovering the insights

View Report


  • Small Cell Lung Cancer
  • Targeted Therapy in Stage I–III NSCLC
  • Oncogene-Driven, Stage IV NSCLC: EGFR/HER2
  • Oncogene-Driven, Stage IV NSCLC: KRAS, MET, ALK
  • Immunotherapy in Stage I–III NSCLC
  • Immunotherapy and Other Approaches in Stage III–IV NSCLC/Subsequent Therapy in Metastatic NSCLC

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.